C&O Pharmaceutical Technology (Holdings) Limited ( China (Mainland))

Listed on the Main Board of the Singapore Exchange in October 2005, C & O Pharmaceutical Technology (Holdings) Limited ("C&O") is an established and integrated pharmaceutical group in China. Its business model spans the entire value chain in the pharmaceutical industry, from research and development, to manufacturing, as well as marketing and distribution of C&O Branded and third party pharmaceutical products via an extensive distribution network covering over 3,000 distributors and 300,000 clinics, pharmacies and hospitals across all parts of China.

Its product portfolio comprises C&O Branded products and Exclusive products, focusing primarily on anti-infective and gastrointestinal drugs, drugs for ageing adults, as well as other specialized drugs such as Feiningda with cas registry number of 82419-36-1, Antaen Gel, Amoxycillin with cas registry number of 26787-78-0, Cefradine with cas registry number of 38821-53-3, Aoshu.

C&O offers one-stop solutions to other pharmaceutical companies both in China and outside of China with its contract research organisation and contract manufacturing organisation services, as well as product registration and distribution services.